Andrea Toomer, MD
Physical Medicine & Rehabilitation · Marrero, LANPI 1063541902
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,625 of the $170,444 with a category attached, or 83.1%. Ipsen Biopharmaceuticals, Inc accounts for 75.5% of it on its own, with 36 other manufacturers making up the rest. Among physical medicine & rehabilitation clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $504.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$129K
- Medtronic$26K
- Piramal Critical Care$9K
- Flowonix Medical Incorporated$5K
- Johnson & Johnson$199
- Amgen$194
- plus $2K from 31 others
What the payments were for
- Consulting fees$11,6977%
- Speaking & faculty fees$141,62583%
- Travel & lodging$9,1485%
- Food & beverage$7,9755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 142 | $128,674 |
| Medtronic(2 entities) | 65 | $25,603 |
| Piramal Critical Care | 19 | $9,301 |
| Flowonix Medical Incorporated | 1 | $4,743 |
| Johnson & Johnson | 6 | $199 |
| Amgen(2 entities) | 11 | $194 |
| Eisai Inc. | 10 | $171 |
| Biogen | 9 | $150 |
| Novartis | 8 | $128 |
| Argenx US, Inc. | 5 | $121 |
| Abbott | 6 | $109 |
| AbbVie(2 entities) | 5 | $100 |
| Merz Pharmaceuticals, LLC | 4 | $94 |
| Saol Therapeutics Inc. | 3 | $73 |
| AstraZeneca(2 entities) | 4 | $57 |
| UCB, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Lundbeck LLC | 2 | $54 |
| Biotronik NRO, Inc. | 2 | $51 |
| Neurelis, Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $44 |
| CSL Behring | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Spinal Simplicity, LLC | 3 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Scilex Pharmaceuticals Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| MDD US Operations, LLC | 1 | $25 |
| Dynasplint Systems Inc. | 1 | $25 |
| Tersera Therapeutics LLC | 2 | $25 |
| Virtus Pharmaceuticals LLC | 1 | $19 |
| Saluda Medical Americas, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Penumbra, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$126,996
- GABLOFEN$36,000
- LIORESAL$14,738
- Prometra II$4,743
- SYNCHROMEDII$3,911
- SYNCHROMED$3,627
- MITIGO$2,400
- INTELLIS ADAPTIVESTIM$2,000
How this compares
$170,444 in reported general payments places this provider in the 95th percentile of 117 physical medicine & rehabilitation providers in Louisiana.
See all physical medicine & rehabilitation providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DysportAbobotulinumtoxina | 46 | $48,566 |
| Buprenorphine | 59 | $11,207 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 356 | $9,908 |
| Dantrolene Sodium | 103 | $8,585 |
| BelbucaBuprenorphine Hcl | 12 | $8,035 |
| Baclofen | 449 | $7,708 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 268 | $7,438 |
| MovantikNaloxegol Oxalate | 14 | $6,474 |
| Gabapentin | 323 | $5,791 |
| OxycontinOxycodone Hcl | 12 | $3,894 |
| Morphine Sulfate ErMorphine Sulfate | 117 | $3,034 |
| Amitriptyline Hcl | 183 | $2,772 |
| Tizanidine Hcl | 137 | $2,688 |
| Pregabalin | 177 | $2,606 |
| Lidocaine | 12 | $2,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ipsen Biopharmaceuticals, IncDysport | $128,674 | $48,56646 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $38 | $8,03512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 physical medicine & rehabilitation providers in Louisiana.
Other physical medicine & rehabilitation in Marrero
- Stephen RynickMarrero$12K
- Meda ColvinMarrero$611
- William RogenmoserAlexandria$350K
- Taylor ColonCovington$26K
- Erik DavisMetairie$12K
- Fred DefranceschMetairie$11K
- Eric FinckeNew Orleans$9K
- Casey MurphyNew Orleans$8K
- Joshua KaufmanNew Orleans$8K
- Navneet SharmaRuston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.